特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
953802

ヒト用混合ワクチンの世界市場:2020年-2024年

Global Human Combination Vaccines Market 2020-2024

出版日: | 発行: TechNavio (Infiniti Research Ltd.) | ページ情報: 英文 120 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.81円
ヒト用混合ワクチンの世界市場:2020年-2024年
出版日: 2020年07月30日
発行: TechNavio (Infiniti Research Ltd.)
ページ情報: 英文 120 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界のヒト用混合ワクチンの市場規模は、2020年から2024年までの間に49億8,000万米ドル拡大すると予測されており、この間のCAGRは9%になる見通しです。市場拡大の原動力となるのは、小児人口の増加、抗ウイルス薬耐性問題の深刻化、感染症の症例増加などの要因です。

当レポートは、世界のヒト用混合ワクチン市場を調査したもので、タイプ別の分析、顧客と各地域市場の分析、ベンダー各社の勢力図とプロファイルなどの情報を提供しています。

目次

エグゼクティブサマリー

市場情勢

市場規模

  • 市況

タイプ別市場

  • 市場の定義
  • 市場区分
  • 市場セグメント分析
  • 2019年の市場規模
  • タイプ別の比較
  • 不活化ワクチン
  • 弱毒生ワクチン

ファイブフォース分析

顧客情勢

各地域の情勢

  • 北米
  • 欧州
  • アジア

タイプ別の市場分析

  • タイプ別比較
  • 主要国
  • 各地域の市場機会
  • 不活化ワクチン
  • 弱毒生ワクチン
  • 市場の牽引役-需要が成長を主導
  • 市場機会
  • 市場の課題
  • 市場動向

顧客情勢

各地域の情勢

  • 北米
  • 欧州
  • アジア
  • その他

ベンダー各社の勢力図

  • ベンダー各社の勢力図
  • 各地域の市場
  • 革新的な動き
  • 各地域の比較

ベンダー各社の分析

  • 対象ベンダー
  • ベンダー各社のポジショニング

ベンダー各社の勢力図

  • ベンダー情勢
  • 革新的な動き

ベンダー分析

  • 対象となるベンダー
  • ベンダー各社のポジショニング
  • Cadila Healthcare Ltd.
  • CSL Ltd.
  • Daiichi Sankyo Co. Ltd.
  • GlaxoSmithKline Plc
  • MassBiologics
  • Meiji Holdings Co. Ltd.
  • Merck & Co. Inc.
  • Mitsubishi Tanabe Pharma Corp.
  • Sanofi
  • Takeda Pharmaceutical Co. Ltd.

付録

目次
Product Code: IRTNTR44620

Technavio has been monitoring the human combination vaccines market and it is poised to grow by $ 4.98 bn during 2020-2024 progressing at a CAGR of 9% during the forecast period. Our reports on human combination vaccines market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increase in the pediatric population, increasing antiviral drug resistance and rise in cases of infectious diseases.

The human combination vaccines market analysis includes type segment and geographic landscape.

Technavio's ‘human combination vaccines market ’ is segmented as below:

By Type:

  • Inactivated vaccine
  • Live attenuated vaccine

By Geographic Landscape:

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the growing interest in R&D of new vaccines as one of the prime reasons driving the human combination vaccines market growth during the next few years. Also, the presence of government-sponsored programs and threats from bioterrorism will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our human combination vaccines market covers the following areas:

  • Human combination vaccines market sizing
  • Human combination vaccines market forecast
  • Human combination vaccines market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading human combination vaccines market vendors that include Cadila Healthcare Ltd., CSL Ltd., Daiichi Sankyo Co. Ltd., GlaxoSmithKline Plc, MassBiologics, Meiji Holdings Co. Ltd., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corp., Sanofi, and Takeda Pharmaceutical Co. Ltd. Also, the human combination vaccines market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Threat of substitutes
  • Market ecosystem
  • Threat of rivalry
  • Value chain analysis

Market Sizing

  • Market condition

Market Segmentation by Type

  • Market definition
  • Market segments
  • Market segment analysis
  • Market size 2019
  • Comparison by Type
  • Inactivated vaccine - Market size and forecast 2019-2024
  • Market outlook: Forecast for 2019 - 2024
  • Live attenuated vaccine - Market size and forecast 2019-2024

Five Forces Analysis

  • Market opportunity by Type
  • Five force analysis
  • Bargaining power of buyers

Customer landscape

Geographic Landscape

  • Bargaining power of suppliers
  • Threat of new entrants
  • Geographic segmentation
  • Geographic comparison
  • Threat of substitutes
  • North America - Market size and forecast 2019-2024
  • Threat of rivalry
  • Europe - Market size and forecast 2019-2024
  • Market condition
  • Asia - Market size and forecast 2019-2024

Market Segmentation by Type

  • ROW - Market size and forecast 2019-2024
  • Market segments
  • Comparison by Type
  • Key leading countries
  • Market opportunity by geography
  • Inactivated vaccine - Market size and forecast 2019-2024
  • Live attenuated vaccine - Market size and forecast 2019-2024
  • Market drivers - Demand led growth
  • Market opportunity by Type
  • Market challenges
  • Market trends

Customer landscape

Geographic Landscape

Vendor Landscape

  • Vendor landscape
  • Geographic segmentation
  • Landscape disruption
  • Geographic comparison

Vendor Analysis

  • North America - Market size and forecast 2019-2024
  • Vendors covered
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • Market positioning of vendors
  • Cadila Healthcare Ltd.
  • ROW - Market size and forecast 2019-2024
  • CSL Ltd.
  • Key leading countries
  • Daiichi Sankyo Co. Ltd.
  • Market opportunity by geography
  • GlaxoSmithKline Plc
  • Market drivers - Demand led growth
  • MassBiologics
  • Market challenges
  • Meiji Holdings Co. Ltd.
  • Market trends

Vendor Landscape

  • Merck & Co. Inc.
  • Vendor landscape
  • Mitsubishi Tanabe Pharma Corp.
  • Landscape disruption
  • Sanofi

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • Scope of the report
  • Currency conversion rates for US$
  • Cadila Healthcare Ltd.
  • Research methodology
  • CSL Ltd.
  • List of abbreviations
  • Daiichi Sankyo Co. Ltd.
  • GlaxoSmithKline Plc
  • MassBiologics
  • Meiji Holdings Co. Ltd.
  • Merck & Co. Inc.
  • Mitsubishi Tanabe Pharma Corp.
  • Sanofi
  • Takeda Pharmaceutical Co. Ltd.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2019 - 2024 ($ million)
  • 13: Global market: Year-over-year growth 2019 - 2024 (%)
  • 14: Five forces analysis 2019 & 2024
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2019
  • 21: Type - Market share 2019-2024 (%)
  • 22: Comparison by Type
  • 23: Inactivated vaccine - Market size and forecast 2019-2024 ($ million)
  • 24: Inactivated vaccine - Year-over-year growth 2019-2024 (%)
  • 25: Live attenuated vaccine - Market size and forecast 2019-2024 ($ million)
  • 26: Live attenuated vaccine - Year-over-year growth 2019-2024 (%)
  • 27: Market opportunity by Type
  • 28: Customer landscape
  • 29: Market share by geography 2019-2024 (%)
  • 30: Geographic comparison
  • 31: North America - Market size and forecast 2019-2024 ($ million)
  • 32: North America - Year-over-year growth 2019-2024 (%)
  • 33: Europe - Market size and forecast 2019-2024 ($ million)
  • 34: Europe - Year-over-year growth 2019-2024 (%)
  • 35: Asia - Market size and forecast 2019-2024 ($ million)
  • 36: Asia - Year-over-year growth 2019-2024 (%)
  • 37: ROW - Market size and forecast 2019-2024 ($ million)
  • 38: ROW - Year-over-year growth 2019-2024 (%)
  • 39: Key leading countries
  • 40: Market opportunity by geography ($ million)
  • 41: Impact of drivers and challenges
  • 42: Vendor landscape
  • 43: Landscape disruption
  • 44: Industry risks
  • 45: Vendors covered
  • 46: Market positioning of vendors
  • 47: Cadila Healthcare Ltd. - Overview
  • 48: Cadila Healthcare Ltd. - Business segments
  • 49: Cadila Healthcare Ltd. - Key offerings
  • 50: Cadila Healthcare Ltd. - Key customers
  • 51: Cadila Healthcare Ltd. - Segment focus
  • 52: CSL Ltd. - Overview
  • 53: CSL Ltd. - Business segments
  • 54: CSL Ltd. - Key offerings
  • 55: CSL Ltd. - Key customers
  • 56: CSL Ltd. - Segment focus
  • 57: Daiichi Sankyo Co. Ltd. - Overview
  • 58: Daiichi Sankyo Co. Ltd. - Business segments
  • 59: Daiichi Sankyo Co. Ltd. - Key offerings
  • 60: Daiichi Sankyo Co. Ltd. - Key customers
  • 61: Daiichi Sankyo Co. Ltd. - Segment focus
  • 62: GlaxoSmithKline Plc - Overview
  • 63: GlaxoSmithKline Plc - Business segments
  • 64: GlaxoSmithKline Plc - Key offerings
  • 65: GlaxoSmithKline Plc - Key customers
  • 66: GlaxoSmithKline Plc - Segment focus
  • 67: MassBiologics - Overview
  • 68: MassBiologics - Product and service
  • 69: MassBiologics - Key offerings
  • 70: MassBiologics - Key customers
  • 71: MassBiologics - Segment focus
  • 72: Meiji Holdings Co. Ltd. - Overview
  • 73: Meiji Holdings Co. Ltd. - Business segments
  • 74: Meiji Holdings Co. Ltd. - Key offerings
  • 75: Meiji Holdings Co. Ltd. - Key customers
  • 76: Meiji Holdings Co. Ltd. - Segment focus
  • 77: Merck & Co. Inc. - Overview
  • 78: Merck & Co. Inc. - Business segments
  • 79: Merck & Co. Inc. - Key offerings
  • 80: Merck & Co. Inc. - Key customers
  • 81: Merck & Co. Inc. - Segment focus
  • 82: Mitsubishi Tanabe Pharma Corp. - Overview
  • 83: Mitsubishi Tanabe Pharma Corp. - Business segments
  • 84: Mitsubishi Tanabe Pharma Corp. - Key offerings
  • 85: Mitsubishi Tanabe Pharma Corp. - Key customers
  • 86: Mitsubishi Tanabe Pharma Corp. - Segment focus
  • 87: Sanofi - Overview
  • 88: Sanofi - Business segments
  • 89: Sanofi - Key offerings
  • 90: Sanofi - Key customers
  • 91: Sanofi - Segment focus
  • 92: Takeda Pharmaceutical Co. Ltd. - Overview
  • 93: Takeda Pharmaceutical Co. Ltd. - Product and service
  • 94: Takeda Pharmaceutical Co. Ltd. - Key offerings
  • 95: Takeda Pharmaceutical Co. Ltd. - Key customers
  • 96: Takeda Pharmaceutical Co. Ltd. - Segment focus
  • 97: Currency conversion rates for US$
  • 98: Research Methodology
  • 99: Validation techniques employed for market sizing
  • 100: Information sources
  • 101: List of abbreviations
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.